These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1031 related articles for article (PubMed ID: 33010669)

  • 1. The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies.
    Seyed Hosseini E; Riahi Kashani N; Nikzad H; Azadbakht J; Hassani Bafrani H; Haddad Kashani H
    Virology; 2020 Dec; 551():1-9. PubMed ID: 33010669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
    Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M
    In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A global treatments for coronaviruses including COVID-19.
    Yousefi B; Valizadeh S; Ghaffari H; Vahedi A; Karbalaei M; Eslami M
    J Cell Physiol; 2020 Dec; 235(12):9133-9142. PubMed ID: 32394467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The broad-spectrum antiviral recommendations for drug discovery against COVID-19.
    Hazafa A; Ur-Rahman K; Haq IU; Jahan N; Mumtaz M; Farman M; Naeem H; Abbas F; Naeem M; Sadiqa S; Bano S
    Drug Metab Rev; 2020 Aug; 52(3):408-424. PubMed ID: 32546018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell responses and therapies against SARS-CoV-2 infection.
    Toor SM; Saleh R; Sasidharan Nair V; Taha RZ; Elkord E
    Immunology; 2021 Jan; 162(1):30-43. PubMed ID: 32935333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
    Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
    IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacterial co-infections with SARS-CoV-2.
    Mirzaei R; Goodarzi P; Asadi M; Soltani A; Aljanabi HAA; Jeda AS; Dashtbin S; Jalalifar S; Mohammadzadeh R; Teimoori A; Tari K; Salari M; Ghiasvand S; Kazemi S; Yousefimashouf R; Keyvani H; Karampoor S
    IUBMB Life; 2020 Oct; 72(10):2097-2111. PubMed ID: 32770825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
    Uzunova K; Filipova E; Pavlova V; Vekov T
    Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innate immunity in COVID-19: Drivers of pathogenesis and potential therapeutic targets.
    Ruenjaiman V; Hirankarn N; Palaga T
    Asian Pac J Allergy Immunol; 2021 Jun; 39(2):69-77. PubMed ID: 34174806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV.
    Milewska A; Chi Y; Szczepanski A; Barreto-Duran E; Dabrowska A; Botwina P; Obloza M; Liu K; Liu D; Guo X; Ge Y; Li J; Cui L; Ochman M; Urlik M; Rodziewicz-Motowidlo S; Zhu F; Szczubialka K; Nowakowska M; Pyrc K
    J Virol; 2021 Jan; 95(4):. PubMed ID: 33219167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases.
    Fung TS; Liu DX
    Annu Rev Microbiol; 2021 Oct; 75():19-47. PubMed ID: 33492978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug treatment options for the 2019-new coronavirus (2019-nCoV).
    Lu H
    Biosci Trends; 2020 Mar; 14(1):69-71. PubMed ID: 31996494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Potential antiviral therapeutics for 2019 Novel Coronavirus].
    Li H; Wang YM; Xu JY; Cao B
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Mar; 43(3):170-172. PubMed ID: 32164080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
    Rohilla S
    Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
    Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
    Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
    Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
    Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Characterization of SARS-CoV-2.
    Dërmaku-Sopjani M; Sopjani M
    Curr Mol Med; 2021; 21(7):589-595. PubMed ID: 33272175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type I IFNs: A Blessing in Disguise or Partner in Crime in MERS-CoV-, SARS-CoV-, and SARS-CoV-2-Induced Pathology and Potential Use of Type I IFNs in Synergism with IFN-
    Anjum FR; Anam S; Abbas G; Mahmood MS; Rahman SU; Goraya MU; Abdullah RM; Luqman M; Ali A; Akram MK; Chaudhry TH
    Viral Immunol; 2021 Jun; 34(5):321-329. PubMed ID: 33181057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.